Some patients who are diagnosed with progressive pulmonary fibrosis (PPF/PFILD) or idiopathic pulmonary fibrosis (IPF) are eligible for anti-fibrotic medication but choose not to take it. This can be a reasonable choice in some instances.
Generally, patients choose to not go on antifibrotics such as nintedanib or pirfenidone if they have concerns about how this may impact their quality of life. Some patients do experience some side effects, which may include losing weight, fatigue, significant diarrhea (more common with nintedanib), developing skin rashes with sun exposure (with pirfenidone) and others. Most patients however tolerate the treatments quite well.
Sometimes, patients who are older or have many other treatments prescribed for other conditions may choose not to go on antifibrotics.
Also, in some cases, they may feel they are too well and the fibrosis does not seem to be getting much worse. In these situations, some may choose to wait and observe the behavior of their condition.

Please leave comments below if you want me to cover other topics in ILD.

☕ Consider supporting my work by "buying a coffee" -- [ Ссылка ]

📚 [ Ссылка ]
🐤 [ Ссылка ]

🎵 Podcast links:
SPOTIFY: [ Ссылка ]
ANCHOR: [ Ссылка ]
GOOGLE PODCASTS: [ Ссылка ]

The opinions presented on this channel are my own and do not constitute medical advice in specific cases. If you are watching/listening to this content as a patient, you must seek personalized advice from your own healthcare team (who can provide you with a consultation and appropriate treatment and advice. This information presented here may not apply in your case. If you are a health professional, please use your professional judgement when treating patients.

свернуть